References
- Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 expert consensus from the transplantion society working group. Transplantation. 2020;104(5):911-22. https://doi.org/10.1097/TP.0000000000003095 PMid:31895348
- Mirzakhani M, Shahbazi M, Akbari R, Dedinská I, Nemati E, Mohammadnia-Afrouzi M. Soluble CD30, the immune response, and acute rejection in human kidney transplantation: A systematic review and meta-analysis. Front Immunol. 2020;11:295. https://doi.org/10.3389/fimmu.2020.00295 PMid:32256486
- Eikmans M, Gielis EM, Ledeganck KJ, Yang J, Abramowicz D, Claas FF. Non-invasive biomarkers of acute rejection in kidney transplantation: Novel targets and strategies. Front Med. 2019;5:358. https://doi.org/10.3389/fmed.2018.00358 PMid:30671435
- Grenzi PC, Campos ÉF, Silva HT Jr., Felipe CR, Franco MF, Soares MF, et al. Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation. Transpl Immunol. 2015;32(2):61-5. https://doi.org/10.1016/j.trim.2015.02.004 PMid:25698648
- Kinch A, Amini RM, Hollander P, Molin D, Sundström C, Enblad G. CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncol. 2020;59(6):673-80. https://doi.org/10.1080/0284186X.2020.1731924 PMid:32102582
- Dong W, Shunliang Y, Weizhen W, Qinghua W, Zhangxin Z, Jianming T, et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol. 2006;16(1):41-5. https://doi.org/10.1016/j.trim.2006.02.005 PMid:16701175
- Vondran FW, Timrott K, Kollrich S, Steinhoff AK, Kaltenborn A, Schrem H, et al. Pre-transplant immune state defined by serum markers and alloreactivity predicts acute rejection after living donor kidney transplantation. Clin Transplant. 2014;28(9):968-79. https://doi.org/10.1111/ctr.12399 PMid:24931031
- Drasch T, Bach C, Luber M, Spriewald B, Utpatel k, Büttner-Herold M, et al. Increased levels of sCD30 have no impact on the incidence of early ABMR and long-term outcome in intermediate-risk renal transplant patients with preformed DSA. Front Med (Lausanne). 2021;8:778864. https://doi.org/10.3389/fmed.2021.778864 PMid:34820407
- Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, et al. Refractory Epstein-barr virus (EBV)-related post-transplant lymphoproliferative disease: Cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes. Front Med (Lausanne). 2019;6:295. https://doi.org/10.3389/fmed.2019.00295 PMid:31921871
- Fadel FI, Bazaraa HM, Badawy H, Morsi HA, Saadi G, Abdel Mawla MA, et al. Pediatric kidney transplantation in Egypt: Results of 10-year single-center experience. Pediatr Transplant. 2020;24(6):e13724. https://doi.org/10.1111/petr.13724 PMid:32388917
- Manti S, Licari A. How to obtain informed consent for research. Breathe (Sheff). 2018;14(2):145-52. https://doi.org/10.1183/20734735.001918 PMid:29875834
- Huang PC, Yang CY, Lee CY, Yeh CC, Yeh CC, Lai IR, et al. Pediatric renal transplantation: Results and prognostic factors. Asian J Surg. 2013;36(2):53-7. https://doi.org/10.1016/j.asjsur.2012.09.001 PMid:23522755
- Fleiner F, Fritsche L, Glander P, Neumayer HH, Budde K. Reporting of rejection after renal transplantation in large immunosuppressive trials: Biopsy-proven, clinical, presumed, or treated rejection? Transplantation. 2006;81(5):655-9. https://doi.org/10.1097/01.tp.0000214933.73927.4e PMid:16534464
- Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16(10):3015-26. https://doi.org/10.1681/ASN.2005050463 PMid:16120819
- Suresh KP, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7-13. https:doi.org/10.4103/0974-1208.97779 PMid:22870008
- Pelzl S, Opelz G, Wiesel M, Schnülle P, Schönemann C, Döhler B, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation. 2002;73(1):3-6. https://doi.org/10.1097/00007890-200201150-00002 PMid:11792970
- Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation. 2005;79(5):599-601. PMid:15753850
- Schaefer SM, Susal C, Opelz G, Dohler B, Becker LE, Klein K, et al. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients. HLA. 2016;87(2):89-99. https://doi.org/10.1111/tan.12735 PMid:26840927
- Nafar M, Farrokhi F, Vaezi M, Entezari AE, Pour-Reza-Gholi F, Firoozan A, et al. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol. 2009;41(3):687-93. https://doi.org/10.1007/s11255-008-9505-x PMid:19142743
- Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: Anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol. 2012;26(2-3):81-7. https://doi.org/10.1016/j.trim.2011.12.002 PMid:22182633
- Kamali K, Abbasi MA, Farokhi B, Abbasi A, Fallah P, Seifee MH, et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant. 2009;7(4):237-40. PMid:20353374
- Süsal C, Pelzl S, Simon T, Opelz G. Advances in pre-and posttransplant immunologic testing in kidney transplantation. Transplant Proc. 2004;36(1):29-34. https://doi.org/10.1016/j.transproceed.2003.11.019 PMid:15013292
- Hamer R, Roche L, Smillie D, Harmer A, Mitchell D, Molostvov G, et al. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation. Transpl Immunol. 2010;23(4):161-5. https://doi.org/10.1016/j.trim.2010.06.004 PMid:20600903
- Abbas K, Muzaffar R, Zafar MN, Mubarak M, Naqvi SA, Rizvi SA. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination. J Pak Med Assoc. 2009;59(4):212-5. PMid:19402280
- Azarpira N, Aghdaie MH, Malekpour Z. Soluble CD30 in renal transplant recipients: Is it a good biomarker to predict rejection? Saudi J Kidney Dis Transpl. 2010;21(1):31-6. PMid:20061689
- Mohamed RR, Elthakaby AH, Ibrahim AH, Mohamed HI, Menyway AA, Elshimy AM, et al. Egyptian study of post-transplant sCD30 as a predictor of kidney graft outcome. Clin Med Diagn. 2019;9(3):55-60. https://doi.org/10.5923/j.cmd.20190903.03
- Marino-Vázquez LA, Ramírez JB, González N, Alberú J, Morales-Buenrostro LE. Effect of soluble CD30 on graft outcome: A single center cohort of kidney transplant recipients. Rev Mex Traspl. 2014;3(3):86-9.
- Chen Y, Tai Q, Hong S, Kong Y, Shang Y, Liang W, et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: A meta-analysis. Transplantation. 2012;94(9):911-8. https://doi.org/10.1097/TP.0b013e31826784ad PMid:23052636
- Halim MA, Al-Otaibi T, Al-Muzairai I, Mansour M, Tawab KA, Awadain WH, et al. Serial soluble CD30 measurements as a predictor of kidney graft outcome. Transplant Proc. 2010;42(3):801-3. https://doi.org/10.1016/j.transproceed.2010.03.033 PMid:20430176
- Slavcev A, Lacha J, Honsova E, Sajdlova H, Lodererova A, Vitko S, et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol. 2005;14(2):117-21. https://doi.org/10.1016/j.trim.2005.03.014 PMid:15935302
- Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol. 2003;12(1):49-61. https://doi.org/10.1016/S0966-3274(03)00014-5 PMid:14551032
- Süsal C, Slavcev A, Pham L, Zeier M, Morath C. The possible critical role of T-cell help in DSA-mediated graft loss. Transpl Int. 2018;31(6):577-84. https://doi.org/10.1111/tri.13126 PMid:29405445
- Arjona A. Soluble CD30 for the prediction and detection of kidney transplant rejection. Drug News Perspect. 2009;22(7):409-13. PMid:19890498
- Chrul S, Polakowska E. Age-dependent changes of serum soluble CD30 concentration in children. Pediatr Transplant. 2011;15(5):515-8. https://doi.org/10.1111/j.1399-3046.2011.01516.x PMid:21672104
- Domingues EM, Matuck T, Graciano ML, Souza E, Rioja S, Falci MC, et al. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection 6 months following renal transplant. Clin Transplant. 2010;24(6):821-9. https://doi.org/10.1111/j.1399-0012.2009.01182.x PMid:20047612
- Wang D, Wu GJ, Wu WZ, Yang SL, Chen JH, Wang H, et al. Pre-and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol. 2007;17(4):278-82. https://doi.org/10.1016/j.trim.2007.02.001 PMid:17493531
- Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation. 2006;81(8):1216-9. https://doi.org/10.1097/01.tp.0000203324.49969.30 PMid:16641611